|
|
Previous Article | Table of Contents | Next Article 
Blood, 15 June 2001, Vol. 97, No. 12, pp. 3902-3909
NEOPLASIA
MCL1 transgenic mice exhibit a high incidence of
B-cell lymphoma manifested as a spectrum of histologic
subtypes
Ping Zhou,
Norman B. Levy,
Haiyi Xie,
Liping Qian,
Chi-Yu Gregory Lee,
Randy D. Gascoyne, and
Ruth W. Craig
From the Departments of Pharmacology and Toxicology,
Pathology, and Community and Family Medicine, Dartmouth Medical School,
Hanover, NH; and Andrology Laboratory, Department of Obstetrics and
Gynecology, University of British Columbia; and Vancouver Cancer
Center, British Columbia Cancer Agency, Vancouver, BC, Canada.
Viability-promoting genes such as BCL2 play an
important role in human cancer but do not directly cause aggressive
tumors. BCL2 transgenic mice develop lymphoma at low
frequency, hindering studies of tumorigenesis and its inhibition in the
presence of such gene products. MCL1 is a member of the
BCL2 family that is highly regulated endogenously and that
promotes cell viability and immortalization when introduced
exogenously. Mice expressing an MCL1 transgene in
hematolymphoid tissues have now been monitored for an extended period
and were found to develop lymphoma with long latency and at high
probability (more than 85% over 2 years). In most cases, the disease
was widely disseminated and of clonal B-cell origin. A variety of
histologic subtypes were seen, prominently follicular lymphoma and
diffuse large-cell lymphoma. MCL1 thus sets the stage for
the development of lymphoma as does BCL2, disease occurring
with high probability and recapitulating a spectrum of subtypes as seen
in human patients. These findings with the transgene underscore the
importance of the normal, highly regulated pattern of MCL1
expression, in addition to providing a model for studying tumorigenesis
and its inhibition in the presence of a viability promoting
BCL2 family member.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. H. Cho, S. Goenka, T. Henttinen, P. Gudapati, A. Reinikainen, C. M. Eischen, R. Lahesmaa, and M. Boothby
PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells
Blood,
March 12, 2009;
113(11):
2416 - 2425.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Su, J.-R. Yang, T. Xu, J. Huang, L. Xu, Y. Yuan, and S.-M. Zhuang
MicroRNA-101, Down-regulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity
Cancer Res.,
February 1, 2009;
69(3):
1135 - 1142.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Coles, C. G.A. Marfella, A. N. Imbalzano, H. A. Steinman, D. S. Garlick, R. M. Gerstein, and S. N. Jones
p37Ing1b Regulates B-Cell Proliferation and Cooperates with p53 to Suppress Diffuse Large B-Cell Lymphomagenesis
Cancer Res.,
November 1, 2008;
68(21):
8705 - 8714.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Ding, L. Huo, J.-Y. Yang, W. Xia, Y. Wei, Y. Liao, C.-J. Chang, Y. Yang, C.-C. Lai, D.-F. Lee, et al.
Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer
Cancer Res.,
August 1, 2008;
68(15):
6109 - 6117.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ruiz-Vela, M. Aggarwal, P. de la Cueva, C. Treda, B. Herreros, D. Martin-Perez, O. Dominguez, and M. A. Piris
Lentiviral (HIV)-based RNA interference screen in human B-cell receptor regulatory networks reveals MCL1-induced oncogenic pathways
Blood,
February 1, 2008;
111(3):
1665 - 1676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. A. Masri, W. Xu, S. A. A. Comhair, K. Asosingh, M. Koo, A. Vasanji, J. Drazba, B. Anand-Apte, and S. C. Erzurum
Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension
Am J Physiol Lung Cell Mol Physiol,
September 1, 2007;
293(3):
L548 - L554.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. De Biasio, J. A. Vrana, P. Zhou, L. Qian, C. K. Bieszczad, K. E. Braley, A. M. Domina, S. J. Weintraub, J. M. Neveu, W. S. Lane, et al.
N-terminal Truncation of Antiapoptotic MCL1, but Not G2/M-induced Phosphorylation, Is Associated with Stabilization and Abundant Expression in Tumor Cells
J. Biol. Chem.,
August 17, 2007;
282(33):
23919 - 23936.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Ding, X. He, W. Xia, J.-M. Hsu, C.-T. Chen, L.-Y. Li, D.-F. Lee, J.-Y. Yang, X. Xie, J.-C. Liu, et al.
Myeloid Cell Leukemia-1 Inversely Correlates with Glycogen Synthase Kinase-3{beta} Activity and Associates with Poor Prognosis in Human Breast Cancer
Cancer Res.,
May 15, 2007;
67(10):
4564 - 4571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Klener, M. Szynal, Y. Cleuter, M. Merimi, H. Duvillier, F. Lallemand, C. Bagnis, P. Griebel, C. Sotiriou, A. Burny, et al.
Insights into Gene Expression Changes Impacting B-Cell Transformation: Cross-Species Microarray Analysis of Bovine Leukemia Virus Tax-Responsive Genes in Ovine B Cells
J. Virol.,
February 15, 2006;
80(4):
1922 - 1938.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. K. Lee, C. R. Isham, S. H. Kaufman, and K. C. Bible
Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy
Mol. Cancer Ther.,
January 1, 2006;
5(1):
138 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Gelinas and E. White
BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis
Genes & Dev.,
June 1, 2005;
19(11):
1263 - 1268.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Rust, G Harms, T Blokzijl, M Boot, A Diepstra, J Kluiver, L Visser, S-C Peh, M Lim, W A Kamps, et al.
High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma
J. Clin. Pathol.,
May 1, 2005;
58(5):
520 - 524.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Park, J. S. Kim, L. Tessarollo, J. D. Owens, L. Peng, S. S. Han, S. Tae Chung, T. A. Torrey, W. C. Cheung, R. D. Polakiewicz, et al.
Insertion of c-Myc into Igh Induces B-Cell and Plasma-Cell Neoplasms in Mice
Cancer Res.,
February 15, 2005;
65(4):
1306 - 1315.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Gerl and D. L. Vaux
Apoptosis in the development and treatment of cancer
Carcinogenesis,
February 1, 2005;
26(2):
263 - 270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Kitada and J. C. Reed
MCL-1 Promoter Insertions Dial-Up Aggressiveness of Chronic Leukemia
J Natl Cancer Inst,
May 5, 2004;
96(9):
642 - 643.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Egle, A. W. Harris, P. Bouillet, and S. Cory
Bim is a suppressor of Myc-induced mouse B cell leukemia
PNAS,
April 20, 2004;
101(16):
6164 - 6169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. W. C. J. van de Donk, D. Schotte, M. M. J. Kamphuis, A. M. W. van Marion, B. van Kessel, A. C. Bloem, and H. M. Lokhorst
Protein Geranylgeranylation Is Critical for the Regulation of Survival and Proliferation of Lymphoma Tumor Cells
Clin. Cancer Res.,
November 15, 2003;
9(15):
5735 - 5748.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Ranger, J. Zha, H. Harada, S. R. Datta, N. N. Danial, A. P. Gilmore, J. L. Kutok, M. M. Le Beau, M. E. Greenberg, and S. J. Korsmeyer
Bad-deficient mice develop diffuse large B cell lymphoma
PNAS,
August 5, 2003;
100(16):
9324 - 9329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. V. Terskikh, T. Miyamoto, C. Chang, L. Diatchenko, and I. L. Weissman
Gene expression analysis of purified hematopoietic stem cells and committed progenitors
Blood,
July 1, 2003;
102(1):
94 - 101.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-H. Yoon, N. W. Werneburg, H. Higuchi, A. E. Canbay, S. H. Kaufmann, C. Akgul, S. W. Edwards, and G. J. Gores
Bile Acids Inhibit Mcl-1 Protein Turnover via an Epidermal Growth Factor Receptor/Raf-1-dependent Mechanism
Cancer Res.,
November 15, 2002;
62(22):
6500 - 6505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Inoshita, K. Takeda, T. Hatai, Y. Terada, M. Sano, J. Hata, A. Umezawa, and H. Ichijo
Phosphorylation and Inactivation of Myeloid Cell Leukemia 1 by JNK in Response to Oxidative Stress
J. Biol. Chem.,
November 8, 2002;
277(46):
43730 - 43734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Z. Rassidakis, R. Lai, T. J. McDonnell, F. Cabanillas, A. H. Sarris, and L. J. Medeiros
Overexpression of Mcl-1 in Anaplastic Large Cell Lymphoma Cell Lines and Tumors
Am. J. Pathol.,
June 1, 2002;
160(6):
2309 - 2310.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. I. Chuang, S. Morefield, C.-Y. Liu, S. Chen, J. M. Harlan, and D. M. Willerford
Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1
Blood,
May 1, 2002;
99(9):
3350 - 3359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Zhang, I. Gojo, and R. G. Fenton
Myeloid cell factor-1 is a critical survival factor for multiple myeloma
Blood,
March 15, 2002;
99(6):
1885 - 1893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Vrana, C. K. Bieszczad, E. S. Cleaveland, Y. Ma, J. P. Park, T. K. Mohandas, and R. W. Craig
An MCL1-overexpressing Burkitt Lymphoma Subline Exhibits Enhanced Survival on Exposure to Serum Deprivation, Topoisomerase Inhibitors, or Staurosporine but Remains Sensitive to 1-{beta}-D-Arabinofuranosylcytosine
Cancer Res.,
February 1, 2002;
62(3):
892 - 900.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|